Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026)
Lexeo Therapeutics (LXEO) posted Return on Capital Employed of 39.86% for Q1 2026, up 30.88% sequentially from 57.67% in Q4 2025, and up 7037.0% YoY from 0.56% in Q1 2025.
Lexeo Therapeutics (LXEO) Return on Capital Employed (2023 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Return on Capital Employed for 4 years, with the latest figure at 39.86% in Q1 2026.
- Quarterly Return on Capital Employed rose 7037.0% year-over-year to 39.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 39.86% (up 7037.0% YoY) and the FY2025 annual result came in at 57.2%, up 3055.0% from the prior year.
- Return on Capital Employed advanced to 39.86% in Q1 2026 per LXEO's latest filing, from 57.67% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 39.86% in Q1 2026 and troughed at 110.23% in Q1 2025.
- A 4-year average of 70.46% and a median of 68.34% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 6341 bps in 2025, then soared 7037 bps in 2026.
- Over 4 years, Return on Capital Employed stood at 85.61% in 2023, then advanced by 10 bps to 76.89% in 2024, then gained by 25 bps to 57.67% in 2025, then soared by 31 bps to 39.86% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 39.86%, 57.67%, and 79.56% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | -40.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.14% |
| Mar 31, 2026 | -39.86% |
| Dec 31, 2025 | -57.67% |
| Sep 30, 2025 | -79.56% |
| Jun 30, 2025 | -103.46% |
| Mar 31, 2025 | -110.23% |
| Dec 31, 2024 | -76.89% |
| Sep 30, 2024 | -59.80% |
| Jun 30, 2024 | -44.68% |
| Mar 31, 2024 | -46.82% |
| Dec 31, 2023 | -85.61% |